Table 4.
Frequency of adverse events during the study period (efficacy population)
Adverse events reported by ≥5% of patients, n (%) | n = 53 |
Insomnia | 12 (22.6) |
Increased prolactin | 9 (17.0) |
Weight gain | 7 (13.2) |
Anxiety | 3 (5.7) |
Epigastralgia | 3 (5.7) |
Reduced appetite | 3 (5.7) |
Adverse events related to the study drug, n (%) | n = 53 |
Increased prolactin | 9 (17.0) |
Weight gain | 5 (9.4) |